Literature DB >> 34533937

Reversing Multidrug Resistance by Inducing Mitochondrial Dysfunction for Enhanced Chemo-Photodynamic Therapy in Tumor.

Chao Shi1, Haiqiao Huang1, Xiao Zhou1, Zhen Zhang1, He Ma1, Qichao Yao1, Kun Shao1, Wen Sun1,2, Jianjun Du1,2, Jiangli Fan1,2, Bin Liu3, Lei Wang3, Xiaojun Peng1,2.   

Abstract

Efficiency of standard chemotherapy is dramatically hindered by intrinsic multidrug resistance (MDR). Recently, to amplify therapeutic efficacy, photodynamic therapy (PDT)-induced mitochondrial dysfunction by decorating targeting moieties on nanocarriers has obtained considerable attention. Nevertheless, low targeting efficiency, complex synthesis routes, and difficulty in releasing contents become the major obstacles in further clinical application. Herein, an ingenious liposomal-based nanomedicine (L@BP) was fabricated by encapsulating a mitochondria-anchored photosensitizer (Cy-Br) and paclitaxel (PTX) for realizing enhanced cooperation therapy. At the cellular level, L@BP could hurdle endosomal traps to localize and implement PDT in mitochondria. Intriguingly, the PDT-induced in situ mitochondrial dysfunction led to intracellular ATP reduction, which triggered the downregulated P-glycoprotein transportation capacity and thus resulted in diminishing the efflux of chemotherapeutic agents and increasing drug uptake by drug-resistant cells. The prepared nanomedicine eminently accumulated in the tumor site and acquired enhanced therapeutic efficiency on PTX-resistant lung cancer cells, which possessed great potential in circumventing MDR tumors.

Entities:  

Keywords:  P-glycoprotein; lysosomal escape; mitochondrial dysfunction; multidrug resistant tumor; synergistic therapy

Mesh:

Substances:

Year:  2021        PMID: 34533937     DOI: 10.1021/acsami.1c12725

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  4 in total

Review 1.  Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.

Authors:  Mohamed Haider; Amr Elsherbeny; Valeria Pittalà; Valeria Consoli; Maha Ali Alghamdi; Zahid Hussain; Ghalia Khoder; Khaled Greish
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

Review 2.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

3.  Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin.

Authors:  Yi Li; Anqi Wu; Lin Chen; Aiting Cai; Yuhao Hu; Zhou Zhou; Qianyi Qi; Yixuan Wu; Donglin Xia; Peixin Dong; Shaoqing Ju; Feng Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-09-07

Review 4.  Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors.

Authors:  Hyung Shik Kim; Dong Yun Lee
Journal:  Biomedicines       Date:  2022-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.